BTNX – Rapid Response COVID-19 Antigen Test – 5 Pack

Order your 5-pack today!

Get the convenience and peace of mind you seek for under $100

Collection Method: Shallow Nasal
Format: Cassette
Time to result: 15 minutes
Quantity: 5 Individual Tests/Box
Volume Pricing: consider ordering boxes of 25 or contact us for a quote

International Orderslearn more & get a quote.

$58.00/box

SKU: BTNX-AG-5PK Categories: , Tags: ,

Order Your 5 Pack of Rapid COVID Tests Today!

The 5 Pack of BTNX Rapid Response® antigen tests is the perfect screening tool for COVID-19.

Put your mind at ease with a 5-pack of BTNX Rapid Response® COVID-19 Antigen Rapid Test Device. It is an efficient, accurate, and reliable method of testing. It is easy to use and delivers results within 15 minutes!

The BTNX Rapid Response™ COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal secretion samples.

Package Contents:

  • 5 Test cassettes
  • 5 Individually packed swabs
  • 5 individually packed buffers
  • 5 tubes and nozzles
  • 1 Tube stand
  • 1 Product insert

Looking for larger orders?

Check out the boxes of 25 BTNX Rapid Response™ COVID-19 Antigen Rapid Test Devices to get the same quality at great savings. Used as part of a comprehensive rapid testing program for COVID-19, the BTNX nasal device offers fast, easy-to-use, and reliable screening. Testing all staff 1-2 times/week helps detect the virus early and decrease the likelihood of spreading COVID-19.

Weight 0.05 lbs
Test TechnologyAntigen
Diagnostic Sensitivity78.6% - 96.2%
Diagnostic Specificity96.5% - 100%
Shelf Life (expiration)12-18 months
Storage Temperature2-30°C/36-86°F
Time to Result15 minutes
Sample CollectionShallow nasal

Instructions

Intended Use

The Rapid ResponseTM COVID-19 Antigen Rapid Test Device is an in vitro immunochromatographic assay for the direct and qualitative detection of SARS-CoV-2 viral nucleoprotein antigens from nasal and nasopharyngeal secretions from individuals suspected of COVID-19 within 6 days of symptom onset and from individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection, when tested twice over two (or three) days with at least 24 hours (and no more than 36 hours) between tests. This test is authorized for use at the Point of Care i.e., in patient care setting.

Results are for the identification of SARS-CoV-2 viral nucleoprotein antigen. Antigens are generally detectable in nasopharyngeal and nasal secretions during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease. Laboratories are required to report all positive results to the appropriate public health authorities.

Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history, and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with
a molecular assay, if necessary, for patient management.

The Rapid ResponseTM COVID-19 Antigen Rapid Test Device is intended for use by trained laboratory personnel or health care professionals.

By purchasing this product, you agree to follow the manufacturer’s intended use and the sale conditions of this website.

Proudly trusted by hundreds of organizations across Canada

Stay up to date with Rapid Test & Trace Canada

Scroll to Top
Tweet
Share
Share
WhatsApp
Pin